ArticleCase reports in dermatological medicine2026
Moxifloxacin-Induced Bullous Acute Generalized Exanthematous Pustulosis (AGEP): A Case Report of a Rare Clinical Presentation.
Article in Case reports in dermatological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) typically characterized by sterile pustules. The bullous variant of AGEP is exceptionally rare and represents a significant diagnostic challenge as it clinically mimics toxic epidermal necrolysis (TEN). We report the case of a 91-year-old woman who developed AGEP following moxifloxacin therapy, which rapidly progressed into a bullous form. A striking and rarely described clinical phenomenon-pustules developing directly on the roof of flaccid bullae-was observed. To our knowledge, this is the first reported case of the bullous variant of AGEP specifically triggered by moxifloxacin. Despite intensive treatment, the patient succumbed to sepsis on Day 15. This case underscores the importance of recognizing atypical AGEP presentations to avoid diagnostic confusion with Stevens-Johnson syndrome (SJS)/TEN and highlights a novel severe reaction to a widely used fluoroquinolone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.